Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/16/2026, 12:00:00 AM
Received European Union approval on March 16, 2026, for Imfinzi combined with chemotherapy for the treatment of resectable, early-stage gastric and gastroesophageal junction (GEJ) cancers, based on positive Phase III MATTERHORN trial results. Medium importance reflects an estimated 5% price impact due to significant market expansion. Scheduled.
Korean Translation
2026년 3월 16일, 긍정적인 3상 MATTERHORN 임상 결과를 바탕으로 절제 가능한 초기 위암 및 위식도 접합부암 치료를 위한 임핀지(Imfinzi)와 화학요법 병용요법이 유럽연합(EU)에서 승인됨. 주요 시장 내 적응증 확대에 따른 5% 이상의 가치 상승을 고려하여 'Medium'으로 분류함. 예정됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
The ex-dividend date for the quarterly cash dividend of $1.25 per share is March 27, 2026, representing a 3% increase over the previous quarterly dividend.
3/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Annual General Meeting 2026 scheduled.
3/26/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
HSBC downgraded the stock from 'Hold' to 'Reduce' with a price target of $850, citing valuation concerns and competitive pressures.
3/22/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Patents for semaglutide, the active ingredient in Ozempic and Wegovy, expired in key markets including China and India. This event opens the door to generic competition in those regions.
3/20/2026, 12:00:00 AM